Valuation
- Market cap
- 5,677,000
- Revenue TTM
- $0
- Net income TTM
- $-6,970,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- -1.08
Trading
- Volume
- 2,900
- Avg volume
- 8,346
- Day's range
- $2.35 – $2.40
- Shares out
- 2,366,000
- Stochastic %K
- 38%
- Beta
- 1.38
- Analysts
- Strong Buy
- Price target
- $6.00
Company profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the resea...
Show more
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 972 5 4228 8897
- Website
- https://www.xtlbio.com
- Address
- 85 Medinat Hayehudim St., Herzliya, Israel
Latest news
No headlines yet.
